Physician

James M Klancnik, MD

According to 2025 Medicare claims, James Klancnik, MD (NPI: 1932134491) practices ophthalmology in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from Kings, NY. This provider's primary affiliated billing organization is VITREOUS RETINA MACULA CONSULTANTS OF NEW YORK (NPI: 1598700791; TIN: 132721177) and primary practice location at 10022-2705.

Klancnik's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,386 traditional Medicare patients, billed 78,303 HCPCS/CPT codes, and received $4,170,428 in Medicare payments. The top billing code was 67028 (Injection of drug into eye). Part D data shows 232 prescription claims across 85 beneficiaries totaling $28,967 in drug costs, led by Alphagan P (Brimonidine Tartrate). Open Payments data shows 10 records totaling $3,255. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs started with an early spike, then settled into a lower baseline, moving from $193,534 to $28,967. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$2.5M$5.1M2015 Medicare payment: $4,368,538 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $4,551,963 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $4,820,441 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $5,067,438 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $4,732,722 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $3,675,247 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $4,296,929 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $4,121,616 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $4,267,090 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $4,170,428 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
201597817,953$4,368,538
20161,01718,222$4,551,963
201799319,812$4,820,441
20181,10620,522$5,067,438
20191,06919,789$4,732,722
202088414,463$3,675,247
20211,04916,584$4,296,929
20221,11220,372$4,121,616
20231,25642,099$4,267,090
20241,38678,303$4,170,428

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$97K$194K2015 Drug cost: $193,534 (USD; Tot_Drug_Cst)2016 Drug cost: $168,464 (USD; Tot_Drug_Cst)2017 Drug cost: $125,922 (USD; Tot_Drug_Cst)2018 Drug cost: $35,875 (USD; Tot_Drug_Cst)2019 Drug cost: $21,225 (USD; Tot_Drug_Cst)2020 Drug cost: $32,926 (USD; Tot_Drug_Cst)2021 Drug cost: $34,265 (USD; Tot_Drug_Cst)2022 Drug cost: $40,405 (USD; Tot_Drug_Cst)2023 Drug cost: $31,366 (USD; Tot_Drug_Cst)2024 Drug cost: $28,967 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015126332$193,534
2016138427$168,464
201770231$125,922
201854125$35,875
201954133$21,225
202065165$32,926
202167181$34,265
202293223$40,405
2023115292$31,366
202485232$28,967

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
67028Injection of drug into eye4741,982$125
92014Established patient complete exam of visual system609669$109
92012Established patient problem focused exam of visual system7302,180$84
92134Imaging of retina1,3173,070$37
92250Photography of the retina1,0391,150$34

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Alphagan PBrimonidine Tartrate11295$2,377
Prednisolone AcetatePrednisolone Acetate26969$1,139
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat291,670$518
LatanoprostLatanoprost332,240$379
MoxifloxacinMoxifloxacin Hcl21407$319

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.8$205Astellas Pharma US Inc
Research PaymentsReported research-related payment or transfer-of-value amount.2$3,050Janssen Research & Development, LLC
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for James M. Klancnik, MD?

Tedicare shows public-source Medicare data for James M. Klancnik, MD (NPI 1932134491), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does James M. Klancnik, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to James M. Klancnik, MD?

James M. Klancnik, MD is linked to VITREOUS RETINA MACULA CONSULTANTS OF NEW YORK (billing NPI 1598700791) in the available physician profile data.

Does James M. Klancnik, MD have Open Payments data?

James M. Klancnik, MD has 10 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.